China advances new drug innovations(2)

2022-04-25 10:33:28China Daily Editor : Li Yan ECNS App Download

A technician extracts active proteins in a laboratory at Harbour BioMed in Shanghai. Chinese companies are making greater contributions to global new drug development. (Photo provided to China Daily)

"China's medicine reforms in recent years have been pushing Chinese companies to increase investments in new drug R&D and innovation to enhance product portfolios, instead of simply profiting from the production and sales of low-quality generics," said Shi Lichen, founder of medical consultancy Beijing Dingchen Consultancy.

"Their innovation and R&D capabilities have been on the rise very fast," he said.

Data from the IQVIA Institute for Human Data Science showed China's share is already 13 percent of all next-generation oncology bio-therapeutics. China-headquartered companies are estimated to be developing 18 percent of all early-stage oncology drugs, up from 6 percent in 2015.

According to Pharmacube, a consultancy focusing on the healthcare sector, Chinese pharmaceutical companies achieved 53 out-license deals with foreign counterparts in 2021, in contrast with 39 out-licenses from 2017 to 2020. A total of 23, or nearly half of the out-license deals last year, were on innovative medicines or candidates.

Those deals include Chinese enterprise BeiGene's two anti-cancer asset out-license agreements with Novartis, which were respectively worth up to $2.2 billion and $2.9 billion.

Liu Jianhong, an analyst with Shanxi Securities, said after years of efforts, China has established a pharmaceutical innovation ecosystem up to global standards to some extent, which enables domestic enterprises to go global more readily, while fierce competition in the domestic market also drives local enterprises to go global for more market returns.

Strengthening investments and R&D to produce not me-too, but rather me-better, best-in-class and even first-in-class drugs have now become a trend in the domestic pharmaceutical industry, Liu said.

According to Wang with HBM, the company is capable of designing unique and novel formats of antibodies, including bispecific and multispecific antibodies.

HBM aims to exponentially enhance the clinical efficacy and safety of these drug candidates which are unachievable by combination therapies, and aspires to lead the next wave of immunotherapies in oncology and immunology, he said.

Susan Galbraith, executive vice-president of oncology R&D at Astra-Zeneca, said the company is excited to enter into the agreement with HBM.

The HBM7022 is designed to harness the body's immune system's T cell response, with potential for strong efficacy across solid tumors, including gastric and pancreatic cancers, both of which comprise large populations of patients with major unmet medical needs, she said.

Related news


Most popular in 24h

MoreTop news


Back to top About Us | Jobs | Contact Us | Privacy Policy
Copyright ©1999-2022 All rights reserved.
Reproduction in whole or in part without permission is prohibited.
[网上传播视听节目许可证(0106168)] [京ICP证040655号]
[京公网安备 11010202009201号] [京ICP备05004340号-1]